The biomarkers predictive of anti-EGFR-based therapy response are well established and are integrated into clinical care for colorectal (CRC) and non-small-cell lung cancer (NSCLC) patients.7,8 However, predictive biomarkers of anti-EGFR-based treatment response in HNSCCs are completely lacking, and these treatments are offered irrespective of the molecular heterogeneity across the tumours. The gene discussed is EGFR; the disease is colorectal carcinoma.